Last checked at 18 Apr 2023 18:22
| 18 April 2023 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 14 April 2023, the Board, following a recommendation from its Remuneration Committee, granted new nil-cost share options to the following Directors/PDMRs under the existing Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP'). The vesting of these options is based on achieving certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) growth against fixed targets and Total Shareholder Return (TSR) against a comparator group. The performance criteria have remained unchanged for the last nine years. Directors/PDMRs are required to hold the LTIPs for a period of two years following vesting.
Director/PDMR | Options prior to grant | Options granted | Resultant LTIP holdings |
Chris Meredith Chief Executive Officer | 733,327
| 324,805
| 1,058,132 |
Eddie Johnson Chief Financial Officer | 317,696
| 134,063
| 451,759 |
Advanced Medical Solutions Group plc also announces that on 14 April 2023, the Board, following a recommendation from its Remuneration Committee, granted new share options to the following Directors/PDMRs under the Advanced Medical Solutions Deferred Annual Bonus Plan (the '2014 DAB').
This award is in respect of the part of their bonus that the Directors/PDMRs are compulsorily required to defer for the 2022 financial year. These options vest at the end of three years. Details of the current DAB holdings of the Directors following these awards are shown below:
Director/PDMR | Options prior to grant/exercise | Options granted | Resultant holding |
Chris Meredith Chief Executive Officer | 6,219 | 31,138 | 37,357 |
Eddie Johnson Chief Financial Officer | 12,737 | 13,528 | 26,265 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
a) | Position/status: Chief Executive Officer | ||||||
b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name: Advanced Medical Solutions Group plc | ||||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
b) | Nature of the transactions: 1. Grant of options under the Advanced Medical Solutions Long Term Incentive Plan 2. Grant of options under the Advanced Medical Solutions Deferred Annual Bonus Plan | ||||||
c) | Price(s) and volume(s): Sale of shares:
| ||||||
d) | Aggregated information: Aggregated volume: n/a Aggregated price: n/a | ||||||
e) | Date of the transaction: 14/04/2023 | ||||||
f) | Place of the transaction: Outside of a trading venue |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: Eddie Johnson | ||||||
2. | Reason for the notification | ||||||
a) | Position/status: Chief Financial Officer | ||||||
b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name: Advanced Medical Solutions Group plc | ||||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
b) | Nature of the transactions: 1. Grant of options under the Advanced Medical Solutions Long Term Incentive Plan 2. Grant of options under the Advanced Medical Solutions Deferred Annual Bonus Plan | ||||||
c) | Price(s) and volume(s): Sale of shares:
| ||||||
d) | Aggregated information: Aggregated volume: n/a Aggregated price: n/a | ||||||
e) | Date of the transaction: 14/04/2023 | ||||||
f) | Place of the transaction: Outside of a trading venue |
- End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations | |
| |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Matthew Neal / Lucy Featherstone | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Gary Clarence / David Anderson | |
HSBC Bank PLC (Broker) | Tel: 44 (0) 20 7991 8888 |
Sam McLennan / Joe Weaving / Stephanie Cornish |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.